|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
Statistics, 2017. CA Cancer J Clin. 67:7–30. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Rahib L, Smith BD, Aizenberg R, Rosenzweig
AB, Fleshman JM and Matrisian LM: Projecting cancer incidence and
deaths to 2030: The unexpected burden of thyroid, liver, and
pancreas cancers in the United States. Cancer Res. 74:2913–2921.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Fogel EL, Shahda S, Sandrasegaran K,
DeWitt J, Easler JJ, Agarwal DM, Eagleson M, Zyromski NJ, House MG,
Ellsworth S, et al: A multidisciplinary approach to pancreas cancer
in 2016: A review. Am J Gastroenterol. 112:537–554. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Neuzillet C, Tijeras-Raballand A, Bourget
P, Cros J, Couvelard A, Sauvanet A, Vullierme MP, Tournigand C and
Hammel P: State of the art and future directions of pancreatic
ductal adenocarcinoma therapy. Pharmacol Ther. 155:80–104. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Burris HA III, Moore MJ, Andersen J, Green
MR, Rothenberg ML, Modiano MR, Cripps MC, Portenoy RK, Storniolo
AM, Tarassoff P, et al: Improvements in survival and clinical
benefit with gemcitabine as first-line therapy for patients with
advanced pancreas cancer: A randomized trial. J Clin Oncol.
15:2403–2413. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Binenbaum Y, Na'ara S and Gil Z:
Gemcitabine resistance in pancreatic ductal adenocarcinoma. Drug
Resist Updat. 23:55–68. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Adesso L, Calabretta S, Barbagallo F,
Capurso G, Pilozzi E, Geremia R, Delle Fave G and Sette C:
Gemcitabine triggers a pro-survival response in pancreatic cancer
cells through activation of the MNK2/eIF4E pathway. Oncogene.
32:2848–2857. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Calabretta S, Bielli P, Passacantilli I,
Pilozzi E, Fendrich V, Capurso G, Fave GD and Sette C: Modulation
of PKM alternative splicing by PTBP1 promotes gemcitabine
resistance in pancreatic cancer cells. Oncogene. 35:2031–2039.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Conroy T, Desseigne F, Ychou M, Bouché O,
Guimbaud R, Bécouarn Y, Adenis A, Raoul JL, Gourgou-Bourgade S, de
la Fouchardière C, et al: FOLFIRINOX versus gemcitabine for
metastatic pancreatic cancer. N Engl J Med. 364:1817–1825. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Von Hoff DD, Ramanathan RK, Borad MJ,
Laheru DA, Smith LS, Wood TE, Korn RL, Desai N, Trieu V, Iglesias
JL, et al: Gemcitabine plus nab-paclitaxel is an active regimen in
patients with advanced pancreatic cancer: A phase I/II trial. J
Clin Oncol. 29:4548–4554. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Von Hoff DD, Ervin T, Arena FP, Chiorean
EG, Infante J, Moore M, Seay T, Tjulandin SA, Ma WW, Saleh MN, et
al: Increased survival in pancreatic cancer with nab-paclitaxel
plus gemcitabine. N Engl J Med. 369:1691–1703. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Vaccaro V, Sperduti I, Vari S, Bria E,
Melisi D, Garufi C, Nuzzo C, Scarpa A, Tortora G, Cognetti F, et
al: Metastatic pancreatic cancer: Is there a light at the end of
the tunnel? World J Gastroenterol. 21:4788–4801. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Lemstrova R, Melichar B and
Mohelnikova-Duchonova B: Therapeutic potential of taxanes in the
treatment of metastatic pancreatic cancer. Cancer Chemother
Pharmacol. 78:1101–1111. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Neesse A, Algül H, Tuveson DA and Gress
TM: Stromal biology and therapy in pancreatic cancer: A changing
paradigm. Gut. 64:1476–1484. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Arumugam T, Ramachandran V, Fournier KF,
Wang H, Marquis L, Abbruzzese JL, Gallick GE, Logsdon CD, McConkey
DJ and Choi W: Epithelial to mesenchymal transition contributes to
drug resistance in pancreatic cancer. Cancer Res. 69:5820–5828.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Koh SB, Mascalchi P, Rodriguez E, Lin Y,
Jodrell DI, Richards FM and Lyons SK: A quantitative FastFUCCI
assay defines cell cycle dynamics at a single-cell level. J Cell
Sci. 130:512–520. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Hosein PJ, de Lima Lopes G Jr, Pastorini
VH, Gomez C, Macintyre J, Zayas G, Reis I, Montero AJ, Merchan JR
and Rocha Lima CM: A phase II trial of nab-Paclitaxel as
second-line therapy in patients with advanced pancreatic cancer. Am
J Clin Oncol. 36:151–156. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Peddi PF, Cho M, Wang J, Gao F and
Wang-Gillam A: Nab-paclitaxel monotherapy in refractory pancreatic
adenocarcinoma. J Gastrointest Oncol. 4:370–373. 2013.PubMed/NCBI
|
